Vivimed Labs Ltd (VIVIMEDLAB):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9846)
◆英語タイトル:Vivimed Labs Ltd (VIVIMEDLAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9846
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Vivimed Labs Ltd (Vivimed) is a supplier of niche molecules and formulations to healthcare, pharmaceuticals and specialty chemicals customers across the world. The company provides active pharmaceutical ingredients (APIs), finished dosage formulations, and specialty chemicals. It manufactures and supplies APIs for hair, skin, oral care; and anti-microbial preservatives for home and personal care market. The company offers contract manufacturing services and the manufacture of branded formulations. It offers a comprehensive range of hair dye intermediates for permanent, semi-permanent and temporary hair coloring, photo chromic dyes, and imaging chemicals. It has presence in India, China, Mauritius, the UK, the US, Spain, and Mexico. Vivimed is headquartered in Hyderabad,Telangana, India.

Vivimed Labs Ltd (VIVIMEDLAB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vivimed Labs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Vivimed Labs Acquires Solid Oral Dosage Facility From Actavis Pharma For US$20 Million 10
Private Equity 11
OrbiMed Asia Invests Additional USD7.5 Million in Vivimed Labs 11
OrbiMed Asia Invests USD42.5 Million in Vivimed Labs 12
OrbiMed Asia Partners to Invest USD42.5 Million in Uquifa 13
Kitara Capital to Acquire Additional Stake in Vivimed Labs for USD2.6 Million 14
Partnerships 15
Strides Shasun Forms Joint Venture with Vivimed Labs 15
CritiTech Enters Into Joint Venture With Finoso Pharma 16
Acquisition 17
Vivimed Labs to Acquire SONEAS Chemicals from Lochlomond and Euroventures 17
Vivimed Labs Acquires Finoso Pharma For US$3 Million 18
Vivimed Labs Ltd – Key Competitors 19
Vivimed Labs Ltd – Key Employees 20
Vivimed Labs Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 23
Legal and Regulatory 23
Oct 05, 2018: Vivimed Labs: update on USFDA inspection at UQUIFA’s facility in Mexico 23
Sep 21, 2017: Vivimeds FDF Facility In Jeedimetla Obtained Ukraine GMP Approval 24
Jun 06, 2017: Vivimed Labs Provides Update on USFDA Inspection at UQUIFA’s Facility 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vivimed Labs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vivimed Labs Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vivimed Labs Acquires Solid Oral Dosage Facility From Actavis Pharma For US$20 Million 10
OrbiMed Asia Invests Additional USD7.5 Million in Vivimed Labs 11
OrbiMed Asia Invests USD42.5 Million in Vivimed Labs 12
OrbiMed Asia Partners to Invest USD42.5 Million in Uquifa 13
Kitara Capital to Acquire Additional Stake in Vivimed Labs for USD2.6 Million 14
Strides Shasun Forms Joint Venture with Vivimed Labs 15
CritiTech Enters Into Joint Venture With Finoso Pharma 16
Vivimed Labs to Acquire SONEAS Chemicals from Lochlomond and Euroventures 17
Vivimed Labs Acquires Finoso Pharma For US$3 Million 18
Vivimed Labs Ltd, Key Competitors 19
Vivimed Labs Ltd, Key Employees 20
Vivimed Labs Ltd, Other Locations 21
Vivimed Labs Ltd, Subsidiaries 21

List of Figures
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vivimed Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Vivimed Labs Ltd (VIVIMEDLAB):製薬・医療:M&Aディール及び事業提携情報(Vivimed Labs Ltd (VIVIMEDLAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆